PAB

0.00%

0.7¢ patrys limited

Ann: Investor update, page-26

First 26 Last

Share
Profile

Follow
Akki

35,673 Posts.

548

05/08/20

13:14

Post #: 46318577
Share

Originally posted by Akki ↑

That was a good juicy update ... wedge will break soon - it loves that high....

Still probably more likely on base once stock is allocated

but who knows tricky position, wedge says sooner and too late once allocated.

Patrys’ lead asset PAT-DX1 exploits the DNA Damage Response (DDR) mechanism to block DNA repair and preferentially kill cancer cells. In animal models, PAT-DX1 has shown efficacy in killing cancer cells with a range of DDR gene mutations such as BRCA2 and PTEN – and importantly it does not kill cells without those mutations (i.e. healthy cells). This could be a game changer in the oncology space. PAT-DX1 is the only known antibody to have shown efficacy as a single agent via the synthetic lethality model. Unlike other antibodies and 98% of small molecules, it can also cross the blood brain barrier (BBB), which provides all-important access to cancer cells in the central nervous system.

Synthetic lethality has also attracted a lot of deal making attention in the past few weeks. In May 2020, Bristol Myers Squibb closed a US$65M deal with Repare Therapeutics for access to its DDR technology platform, and Glaxo Smith Kline inked a deal with IDEAYA Biosciences for three discovery-stage synthetic lethality assets (US$100M upfront, US$20M equity investment, potential development and regulatory milestone payments of around US$465-485M and commercial milestones of US$475M for two of the more advanced programs). It is clear that big pharma and big biotech are increasingly compelled by the elegance of synthetic lethality and DDR therapeutic approaches for treating a range of tumours.

Patrys is in the enviable position of developing a novel therapeutic that combines the established safety and toxicology advantages of antibody therapeutics with the power of synthetic lethality – and it is designed to ‘topple’ the most stubborn, hard-to-reach cancers.

Expand

Might take a few weeks for the fresh allocation to balance ... but it's up from there.

Would be surprised if there wasn't some juicy news towards end of 3Q or early next.

PAB Price at posting: 1.3¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 13 more messages in this thread...

First 26 Last

Add PAB (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $14.40M

Open	High	Low	Value	Volume
0.7¢	0.7¢	0.7¢	$9.941K	1.420M

Buyers (Bids)

No.	Vol.	Price($)
2	51753	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	1638632	8

View Market Depth

No.	Vol.	Price($)
2	51753	0.007
18	4150686	0.006
8	3459992	0.005
5	4174000	0.004
4	2729016	0.003

Price($)	Vol.	No.
0.008	1638632	8
0.009	108695	1
0.010	1806000	4
0.011	1600000	3
0.012	292407	2

Last trade - 14.08pm 28/06/2024 (20 minute delay)

PAB (ASX) Chart

Ann: Investor update, page-26

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor update, page-26

Top Stories

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News